Pipex Pharmaceuticals Partners With VA to Study Coprexa

Pipex Pharmaceuticals has entered a cooperative research and development agreement with the Veterans Affairs (VA) Medical Center in Ann Arbor, Mich., to evaluate Coprexa.

Coprexa (oral tetrathiomolybdate) is the company’s lead anticopper drug candidate in preclinical studies as a treatment for Huntington’s disease.

Steve Kanzer, Pipex’s chairman and CEO, said Coprexa’s selective nature allows it to reduce free copper levels and insoluble amyloid-beta by 40 percent in a murine Alzheimer’s disease model.